EL7.AI
Stocks•14 July 2026•
1 min read

Esperion Therapeutics Removed from S&P Global BMI Index, Adding to Outflow Pressure

Key Facts

1S&P Capital IQ announced the removal of Esperion Therapeutics from the S&P Global BMI Index.
2This removal follows previous exclusions of the company from Russell benchmarks earlier in July.

In a move reflecting the shifting landscape for small-cap biotech firms, S&P Capital IQ has officially announced the removal of Esperion Therapeutics from the S&P Global BMI Index. This exclusion marks the second major index delisting for the company this month, following its removal from the Russell benchmarks in early July. The decision stems from S&P Global's periodic rebalancing and eligibility reviews.

Historically, index removals trigger forced selling by passive funds and ETFs that track these benchmarks, potentially exacerbating downward pressure on the stock's liquidity. Compared to industry peers, Esperion has struggled to maintain the market capitalization thresholds required for major index inclusion, particularly following volatility in its clinical development pipeline according to market reports.

Looking ahead, the broader biotech sector will be sensitive to the FOMC Minutes scheduled for July 8, 2026, which may dictate risk appetite for growth-oriented equities.